Micro-lesson · Module 2
Half-life does not prescribe a schedule
Interpret half-life and accumulation without inventing a regimen.
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.

Learning objective: Interpret half-life and accumulation without inventing a regimen.
The concept
Half-life is the time required for a concentration to decrease by half in a defined phase. In a simple first-order model, it depends on the volume of distribution and clearance. This relationship assumes conditions that must be reviewed before applying it. If a new dose is administered before the previous one is completely eliminated, accumulation can occur. With a fixed repeated dosing regimen and stable pharmacokinetics that permit a finite steady state, the amount of drug reaching the systemic circulation over each dosing interval approaches the amount eliminated. Concentrations may still rise and fall within each interval. This steady state does not require a flat concentration.
Check your understanding
Two preparations have similar reported half-lives. May their routes and administration schedules be exchanged automatically?
Answer and explanation
No. Similar half-lives do not establish equivalent absorption, peak concentration, total exposure, or clinical performance. Repeated administration also changes the concentration profile. Compare the studied product, route, formulation, and evidence before discussing equivalence. Half-life is one parameter, not an independent prescribing instruction.
Continue learning
Explore Module 2 in PEPTIDE Academy for the complete lesson and further case discussion.
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
- Grogan S, Preuss CV. 2023. Pharmacokinetics. Stat Pearls Publishing. Update July 30, 2023. Reference chapter. PMID 32491676. · PMID 32491676
- Overgaard RV, Navarria A, Ingwersen SH, et al. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clin Pharmacokinet. 2021;60(10):1335-1348. DOI: 10.1007/s40262-021-01025-x. PMID: 33969456.DOI 10.1007/s40262-021-01025-x · PMID 33969456
- Wadhwa RR, Cascella M. 2023. Steady-state concentration. StatPearls Publishing. Updated March 6, 2023. Reference chapter; NBK553132.
Related resources

Article · Module 2
Peptide pharmacodynamics: affinity, potency, and efficacy
Two molecules can bind the same receptor and still differ in the concentration required, the response produced, and their unwanted effects. Pharmacodynamics provides the language to describe those differences.

Article · Module 2
Exposure over time: peptide pharmacokinetics and half-life
The administered amount is only one part of drug exposure. Absorption, distribution, elimination, and repeated administration determine how concentrations change over time.

Article · Module 2
Immunogenicity, adverse events, and interactions: reading peptide safety
Safety assessment asks what happened, under which exposure, in whom, and how reliably it can be attributed to an intervention. An isolated antibody result or symptom rarely answers all of those questions.